Oncogenes

Written by

in

 

Oncogenes: Drivers of Unchecked Cellular Proliferation

Oncogenes are mutated or overexpressed variants of normal cellular genes known as proto-oncogenes, which typically encode components of growth signaling pathways. Unlike tumor suppressor genes, oncogenes act through a gain-of-function mechanism. This means that an activating mutation in just a single allele (dominant expression pattern) is sufficient to drive autonomous cellular proliferation, evasion of apoptosis, and malignant transformation.

1. Mechanisms of Proto-Oncogene Activation

Proto-oncogenes convert into active oncogenes via structural genomic alterations that alter protein production levels or functional stability:

Diagram showing proto-oncogene activation mechanisms including coding mutations leading to abnormal proteins, regulatory mutations or gene amplification causing excessive amounts of normal protein, and translocations creating novel fusion proteins

Molecular routes of oncogenic activation: Structural alterations can create constitutively active hyperfunctional products or generate vast protein quantities via amplification and transcriptional dysregulation.
  • Chromosomal Translocation:
    The physical relocation of a genomic segment can splice a proto-oncogene downstream of a highly active promoter, or merge it with another gene to form a chimeric, constitutively hyperactive fusion protein.
  • Gene Amplification:
    The erroneous duplication of focal DNA segments creates hundreds of copies of a proto-oncogene. This manifests cytogenetically as small, extra-chromosomal fragments (double minutes) or integrated homogeneous staining regions (HSRs), driving massive protein overproduction.
  • Point Mutation:
    A single nucleotide change within the coding region can alter a critical regulatory domain, preventing protein inactivation or rendering it resistant to typical structural breakdown pathways.

2. High-Yield Oncogenes and Associated Malignancies

Categorizing oncogenes by their native functional roles inside signaling pathways helps frame their diagnostic value on licensing exams:

Gene Native Biological Function Activation Method Associated Clinical Malignancy
ALK Receptor tyrosine kinase signaling. Inversion on chromosome 2p Adenocarcinoma of the lung (EML4-ALK fusion product).
BCR-ABL Non-receptor tyrosine kinase. t(9;22) translocation
(Philadelphia chromosome)		 Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL).
BCL-2 Anti-apoptotic protein that stabilizes the outer mitochondrial membrane. t(14;18) translocation Follicular Lymphoma (places BCL-2 under the heavy Ig chain promoter).
BRAF Serine/threonine kinase within the MAPK proliferative cascade. Point mutation (V600E) Cutaneous Melanoma, Papillary Thyroid Carcinoma, and Hairy Cell Leukemia.
c-MYC Nuclear transcription factor promoting rapid cell cycle progression. t(8;14) translocation Burkitt Lymphoma (starry-sky appearance on biopsy panels).
HER2/neu
(ERBB2)		 Epidermal growth factor receptor tyrosine kinase family member. Focal Gene Amplification Aggressive variants of Breast Cancer and Gastric Carcinomas.
JAK2 Non-receptor tyrosine kinase linked to erythropoietin receptors. Point mutation (V617F) Chronic Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia).
KRAS GTPase molecular switch in the RAS/MAPK downstream loop. Point mutation (locks protein in GTP-bound active state) Pancreatic Adenocarcinoma, Colorectal Cancer, and Non-Small Cell Lung Cancer.
N-MYC
(MYCN)		 Nuclear transcription factor. Focal Gene Amplification Advanced Pediatric Neuroblastoma.
RET Receptor tyrosine kinase controlling cellular growth and survival. Point mutation or rearrangement Multiple Endocrine Neoplasia (MEN) type 2A and 2B syndromes, Medullary Thyroid Carcinoma.